Early movers: AAPL, TGT, SNE, JPM, CALM, TM & more
Check out which companies are making headlines before the bell:
Apple–The iPhone maker's board recommended shareholders vote against investor Carl Icahn's proposal that Apple buy back $50 billion in shares in fiscal 2014. The company said it had already returned $43 billion to shareholders during the first six months of a $100 billion capital return program.
Crocs–The company is receiving a $200 million investment from Blackstone Group, giving the private equity firm a 13 percent stake. Separately, the shoe company said CEO John McCarvel will retire in April.
Cooper Tire–The company has terminated its takeover agreement with India's Apollo Tyres, following a long legal battle in which Apollo sought to cut the $35/share price it agreed to pay for Cooper back in June.
Cal-Maine Foods–The nation's largest egg producer reported quarterly profit of $1.08 per share, three cents above estimates. The company said it's benefited from acquisitions as well as higher prices.
Sony–Sony has decided not to sell the unit that makes lithium-ion batteries, according to the Nikkei business daily. The paper said talks to sell the unit had stalled and that Sony now believes circumstances are right to turn that business around.
JPMorgan Chase–The mega-bank ramped up its China hiring program after losing deals to competitors, according to a story in today's New York Times. The paper said JPM's competitors were more actively recruiting children of powerful China officials. A number of major Wall Street investment banks have been previously reported to be under scrutiny for their China hiring practices.
Target–The embattled big box retailer remains a stock to watch, following the ongoing controversy over its breached credit card data. Target came under fire Friday for reversing a previous stance and saying encrypted PIN numbers were stolen, although the mechanism used to decrypt that information was not and that the numbers were safe.
Forest Labs–Options activity is pointing to a bullish attitude regarding the drug maker's stock, according to a Dow Jones report.
—By CNBC's Peter Schacknow
Questions? Comments? Email us at firstname.lastname@example.org